On the contrary, patients with age ≥50 years or/and AFP ≥8 ng/mL had a significantly higher risk of HCC compared with those with age <50 years and AFP <8 ng/mL; therefore, these patients should be closely monitored for HCC occurrence during NUC therapy. The gene discussed is AFP; the disease is hepatocellular carcinoma.